Detail akcie Vertex Pharma online

Business Summary: Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Financial Summary: BRIEF: For the fiscal year ended 31 December 2025, Vertex Pharmaceuticals Inc revenues increased 9% to $12B. Net income totaled $3.95B vs. loss of $535.6M. Revenues reflect TRIKAFTA segment increase of 1% to $10.31B, Other CF products segment increase of 5% to $820.1M, United States segment increase of 13% to $7.55B, Other segment increase of 13% to $992.4M. Net Income reflects Research & Development Expense decrease of 97% to $133M (expense).